Renamed to Standard BioTools Inc in June 2022
FLDM - Fluidigm Corporation
NASDAQ
->
Healthcare
->
Diagnostics & Research
South San Francisco,
United States
Type: Equity
FLDM price evolution
FLDM
| (in millions $) | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.45 | $29.31 | $30.86 | $49.74 |
| Short term investments | ||||
| Net receivables | $18.32 | $13.73 | $15.67 | $15.41 |
| Inventory | $20.82 | $24.5 | $25.07 | $21.89 |
| Total current assets | $72.07 | $73.47 | $78.21 | $96.33 |
| Long term investments | ||||
| Property, plant & equipment | $65.15 | $66.61 | $66.44 | $61.03 |
| Goodwill & intangible assets | $134.31 | $137.42 | $140.57 | $143.46 |
| Total noncurrent assets | $203.15 | $208.72 | $211.11 | $208.87 |
| Total investments | ||||
| Total assets | $275.21 | $282.19 | $289.31 | $305.2 |
| Current liabilities | ||||
| Accounts payable | $10.6 | $10.79 | $11.22 | $12.55 |
| Deferred revenue | $39.56 | $42.32 | $48.72 | $43.59 |
| Short long term debt | $9.89 | $2.87 | $2.97 | $3.02 |
| Total current liabilities | $49.57 | $47.29 | $52.85 | $53.53 |
| Long term debt | $101.76 | $102.21 | $93 | $91.26 |
| Total noncurrent liabilities | $131.05 | $135.56 | $127.02 | $128.73 |
| Total debt | $111.65 | $105.09 | $95.97 | $94.28 |
| Total liabilities | $180.62 | $182.85 | $179.87 | $182.26 |
| Shareholders' equity | ||||
| Retained earnings | -$736 | -$726.57 | -$712.73 | -$695.58 |
| Other shareholder equity | -$0.91 | -$0.73 | -$0.28 | -$0.33 |
| Total shareholder equity | $94.6 | $99.34 | $109.45 | $122.94 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.45 | $68.52 | $21.66 | $95.4 |
| Short term investments | $36.98 | |||
| Net receivables | $18.32 | $25.42 | $18.98 | $16.65 |
| Inventory | $20.82 | $19.69 | $13.88 | $13 |
| Total current assets | $72.07 | $117.66 | $96.1 | $127.11 |
| Long term investments | ||||
| Property, plant & equipment | $65.15 | $55.65 | $12.92 | $8.82 |
| Goodwill & intangible assets | $134.31 | $146.77 | $150.31 | $161.51 |
| Total noncurrent assets | $203.15 | $207.09 | $168.72 | $176.54 |
| Total investments | $36.98 | |||
| Total assets | $275.21 | $324.76 | $264.81 | $303.65 |
| Current liabilities | ||||
| Accounts payable | $10.6 | $9.22 | $6.51 | $4.03 |
| Deferred revenue | $39.56 | $42.5 | $19.97 | $17.79 |
| Short long term debt | $9.89 | $2.97 | $1.83 | |
| Total current liabilities | $49.57 | $54.25 | $32.82 | $37.58 |
| Long term debt | $101.76 | $92.4 | $58.14 | $172.06 |
| Total noncurrent liabilities | $131.05 | $131.46 | $78.38 | $193.95 |
| Total debt | $111.65 | $95.38 | $59.98 | $172.06 |
| Total liabilities | $180.62 | $185.71 | $111.2 | $231.53 |
| Shareholders' equity | ||||
| Retained earnings | -$736 | -$676.76 | -$623.64 | -$558.85 |
| Other shareholder equity | -$0.91 | $0.11 | -$0.58 | -$0.69 |
| Total shareholder equity | $94.6 | $139.05 | $153.61 | $72.12 |
| (in millions $) | 31 Jan 2022 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $28.5 | $31.02 | $32.79 | |
| Cost of revenue | $14.84 | $14.6 | $13.75 | |
| Gross Profit | $13.67 | $16.42 | $19.04 | |
| Operating activities | ||||
| Research & development | $9.21 | $9.44 | $10.75 | |
| Selling, general & administrative | $24.07 | $24.25 | $27.61 | |
| Total operating expenses | $33.28 | $33.69 | $38.36 | |
| Operating income | -$19.61 | -$17.27 | -$19.32 | |
| Income from continuing operations | ||||
| EBIT | -$14.3 | -$16.76 | -$19.61 | |
| Income tax expense | -$1.42 | -$0.52 | -$1.67 | |
| Interest expense | $0.97 | $0.9 | $0.89 | |
| Net income | ||||
| Net income | -$13.84 | -$17.14 | -$18.82 | |
| Income (for common shares) | -$13.84 | -$17.14 | -$18.82 | |
| (in millions $) | 31 Jan 2022 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $138.14 | $117.24 | $112.96 | |
| Cost of revenue | $54.82 | $52.96 | $51.31 | |
| Gross Profit | $83.33 | $64.28 | $61.65 | |
| Operating activities | ||||
| Research & development | $36.46 | $31.64 | $30.03 | |
| Selling, general & administrative | $97.9 | $84.48 | $79.78 | |
| Total operating expenses | $134.36 | $116.12 | $109.81 | |
| Operating income | -$51.04 | -$51.84 | -$48.16 | |
| Income from continuing operations | ||||
| EBIT | -$50.53 | -$62.43 | -$47.53 | |
| Income tax expense | -$1.08 | -$1.92 | -$2.41 | |
| Interest expense | $3.57 | $4.28 | $13.89 | |
| Net income | ||||
| Net income | -$53.02 | -$64.79 | -$59.01 | |
| Income (for common shares) | -$53.02 | -$64.79 | -$59.01 | |
| (in millions $) | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Net income | -$9.43 | -$13.84 | -$17.14 | -$18.82 |
| Operating activities | ||||
| Depreciation | $1.03 | $1.01 | $1.03 | $1.08 |
| Business acquisitions & disposals | -$0.68 | $2 | ||
| Stock-based compensation | $4.36 | $4.32 | $3.74 | $3.68 |
| Total cash flows from operations | -$7 | -$9.49 | -$14.66 | -$12.9 |
| Investing activities | ||||
| Capital expenditures | -$0.46 | -$1.71 | -$4.17 | -$6.92 |
| Investments | ||||
| Total cash flows from investing | -$1.15 | -$1.71 | -$4.17 | -$4.92 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.6 | -$0 | $0.89 | |
| Net borrowings | $6.84 | $10 | -$0.5 | |
| Total cash flows from financing | $7.3 | $9.82 | -$0.13 | -$1.03 |
| Effect of exchange rate | -$0.01 | -$0.17 | $0.09 | $0.07 |
| Change in cash and equivalents | -$0.86 | -$1.55 | -$18.88 | -$18.78 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$59.24 | -$53.02 | -$64.79 | -$59.01 |
| Operating activities | ||||
| Depreciation | $4.15 | $6.03 | $4.61 | $5.37 |
| Business acquisitions & disposals | $1.32 | $15.88 | ||
| Stock-based compensation | $16.1 | $14.45 | $11.39 | $11.02 |
| Total cash flows from operations | -$44.06 | -$15.42 | -$35.21 | -$25.2 |
| Investing activities | ||||
| Capital expenditures | -$13.26 | -$12.72 | -$2.53 | -$0.37 |
| Investments | $36.81 | -$36.77 | $5.09 | |
| Total cash flows from investing | -$11.95 | $39.98 | -$39.3 | $4.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.49 | $22 | $2.13 | $60.88 |
| Net borrowings | $16.34 | $3.17 | ||
| Total cash flows from financing | $15.96 | $20.86 | $2.79 | $57.66 |
| Effect of exchange rate | -$0.02 | $0.39 | $0.06 | $0.17 |
| Change in cash and equivalents | -$40.07 | $45.8 | -$71.67 | $37.34 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 76.92M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.24 |
| Cash/Share | 0.37 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.91 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.45 |
| Quick ratio | 1.03 |